3-(2-(4-(2-cyanophenyl)piperazin-1-yl)ethyl)quinazolin-4(3H)-one | 1367624-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(2-(4-(2-cyanophenyl)piperazin-1-yl)ethyl)quinazolin-4(3H)-one
• 英文别名: 3-(2-(4-(2-cyanophenyl)piperazine-1-yl)ethyl)quinazoline-4(3H)-one；2-[4-[2-(4-Oxoquinazolin-3-yl)ethyl]piperazin-1-yl]benzonitrile
• CAS: 1367624-65-4
• 化学式: C₂₁H₂₁N₅O
• 分子量: 359.431
• InChiKey: JZXOIYPCMMQNPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR TRAITER DES TROUBLES ASSOCIÉS AUX RÉCEPTEURS 5-HT1A ET 5-HT2A
  申请人：ACHE LAB FARMACEUTICOS SA

  公开号：WO2012037634A1

  公开（公告）日：2012-03-29

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  这项发明涉及与烷基-哌嗪基苯基4(3H)-喹唑啉酮通式(I)化合物相关，这些化合物在药理学上活跃，并能通过促进对5-HT1A和5-HT2A 5-羟色胺受体的作用来控制、缓解或治疗与这些受体相关的疾病，并且含有这些化合物的药物组合物用于治疗与这些受体相关的疾病。这些化合物及其药物组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、恐慌、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等疾病方面具有用处，这些疾病与这些受体有关。
• Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors
  申请人：ACHÉ INTERNATIONAL (BVI) LTD.

  公开号：US20140303179A1

  公开（公告）日：2014-10-09

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT 1A and 5-HT 2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯基4（3H）-喹唑啉酮通式（I）化合物，这些化合物具有药理活性，并能够通过促进对5-HT1A和5-HT2A血清素受体的作用，有助于控制、缓解或治愈与这些受体相关的疾病，以及包含这些化合物的制药组合物，用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、惊恐症、精神病、进食和睡眠障碍、强迫症以及女性性功能障碍等与这些受体相关的疾病方面具有用途。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS
  申请人：Freire Torres Russo Valter

  公开号：US20130184286A1

  公开（公告）日：2013-07-18

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯4(3H)-喹唑酮通式(I)化合物，这些化合物具有药理活性，并能够以促进对5-HT1A和5-HT2A血清素受体的作用来控制、缓解或治愈与这些受体相关的疾病，并且包含这些化合物的制药组合物可用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动、惊恐、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等与这些受体相关的其他疾病方面非常有用。
• A COMPOUND FOR USE IN THE TREATMENT OF COMORBID ANXIETY DISORDER AND DEPRESSION DISORDER
  申请人：Aché Laboratórios Farmacêuticos S.A.

  公开号：EP3130339A1

  公开（公告）日：2017-02-15

  The present invention relates to a compound for use in the treatment of comorbid anxiety disorder and depression disorder, as well as for preventing depression disorders in individuals affected by anxiety disorders, wherein the compound is selected from the group presenting the general formula (I): wherein R1 is -OCH3 or -CN or suitable pharmaceutical salts, hydrates or anhydrates thereof.

  本发明涉及一种用于治疗合并焦虑症和抑郁症以及预防焦虑症患者抑郁症的化合物，其中该化合物选自通式（I）所示的组： 其中 R1 是 -OCH3 或 -CN 或其合适的药用盐、水合物或无水物。
• US8735578B2
  申请人：——

  公开号：US8735578B2

  公开（公告）日：2014-05-27